

**PLEASE POST & DISTRIBUTE TO ALL NURSING AND MEDICAL STAFF**

**Sign Up to Receive this Update by E-Mail (You receive a better copy and everyone can subscribe.)**

Subscribe at: [https://public.govdelivery.com/accounts/OKSDH/subscriber/new?topic\\_id=OKSDH\\_79](https://public.govdelivery.com/accounts/OKSDH/subscriber/new?topic_id=OKSDH_79).

All interested staff may subscribe, as there is no limit to the number of subscribers. You may cancel your subscription at any time.

**Nine Valent HPV Vaccine Available through the Vaccines for Children Program**

Gardasil 9<sup>®</sup> is now available through the Vaccines for Children (VFC) Program for eligible children 9 through 18 years of age. Orders may be placed in OSIS using the “Force Order” feature. Automatic re-orders will be set in the future. Shipments of the vaccine will begin in June.

**NEW Advisory Committee on Immunization Practices (ACIP) Recommendations for Human Papillomavirus Vaccination**

- HPV9 (Gardasil 9<sup>®</sup>), HPV4 (Gardasil<sup>®</sup>), or HPV2 (Cervarix<sup>®</sup>) for routine vaccination of females 11 or 12 years\* of age and females through 26 years of age who have not been vaccinated previously or who have not completed the 3-dose series.
- HPV9 or HPV4 for routine vaccination of males 11 or 12 years\* of age and males through 21 years of age who have not been vaccinated previously or who have not completed the 3-dose series.
- HPV9 or HPV4 vaccination for men who have sex with men and immunocompromised men (including those with HIV infection) through age 26 years if not vaccinated previously.

\*Can be given starting at 9 years of age.

If vaccination providers do not know or do not have available the HPV vaccine product previously administered to the patient, or are in a clinical setting transitioning to HPV9, any available HPV vaccine may be used to continue or complete the series for females to protect against HPV types 16 and 18. HPV9 or HPV4 may be used to complete the series in males. This recommendation will be incorporated in the immunization schedules to be published in February 2016. Complete HPV9 vaccine recommendations are available at:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm>.

“Compared with current HPV vaccines, which protect against 70% of cervical cancers, 9vHPV (*9-valent HPV vaccine*) has the potential to prevent 90% of cervical cancers.” (Joura EA et al. N Engl J Med. 2015;372[8]:711-723).

**NEW Meningococcal B Vaccines Available**

Recently two meningococcal B (MenB) vaccines were licensed in the U.S.: Trumenba<sup>®</sup>, manufactured by Pfizer, and Bexsero<sup>®</sup>, manufactured by Novartis. Both of these vaccines are licensed for use in individuals 10 through 25 years of age. The ACIP has not yet published recommendations for the use of these vaccines but the vaccines are available through the VFC Program for eligible children. Children eligible to receive these vaccines through the VFC Program are those aged 10 through 18 years who meet one or more of the following criteria:

- Children who have persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H or factor D or taking eculizumab [Soliris<sup>®</sup>]);
- Children who have anatomic or functional asplenia, including sickle cell diseases;
- Children identified to be at risk because of a meningococcal disease outbreak attributable to serogroup B.

Children who do not fall into one of these groups are not eligible to receive VFC MenB vaccines at this time. At the upcoming ACIP meeting in June consideration will be given to whether or not the vaccine should be recommended for the entire population. Orders for these vaccines may be placed in OSIS using the “Force Order” feature. Trumenba is given in a 3-dose series and Bexsero is given in a 2-dose series.

**Updated Vaccine Information Statements (VIS)**

- Gardasil 9 (HPV9)
  - May be used immediately.The VIS for 4-valent Gardasil (HPV4) should not be used when administering Gardasil 9.
- Rotavirus vaccine
  - Does not differ significantly from the interim edition it replaces.
  - Ideally, vaccine providers should begin using the new version now but existing copies of the 8/26/13 edition may be used until stocks are depleted.
- Pneumococcal Polysaccharide vaccine (PPSV23)
  - Does not differ significantly from the previous version.
  - Previous stocks may be used until depleted.

All VIS are available at:

<http://www.cdc.gov/vaccines/hcp/vis/current-vis.html>